Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34474799 | 0.91 | TDP1 (0.47) | CA12CA1CA2CA9DRD2 | |
| SCHEMBL29990322 | 0.84 | CA12 (0.41) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2878788 | 0.84 | CA1 (0.44) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1568982 | 0.83 | CPB2 (0.41) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL12427151 | 0.82 | AAK1 (0.40) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1568120 | 0.81 | STK17B (0.40) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2878417 | 0.80 | TAAR1 (0.46) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL21404585 | 0.78 | CPB2 (0.34) | — | |
| SCHEMBL19027921 | 0.76 | CA1 (0.44) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL12599577 | 0.76 | ALDH1A1 (0.41) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-24 | — | — | US | disclosed |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-13 | — | — | US | disclosed |
| CN-112165944-A | Imidazopiperazine inhibitors of transcriptional activator proteins | 德州大学系统董事会 | 2021-01-01 | — | — | CN | disclosed |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-03 | — | — | US | disclosed |
| WO-2019191667-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-03 | — | — | WO | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| EP-2307417-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| WO-2009156951-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156951-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-30 | — | — | WO | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | CA12 4605/4885CA1 4673/4885CA2 4135/4885 |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | CA12 4605/4885CA1 4673/4885CA2 4135/4885 |
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | HCRTR1, HCRTR2, NPY5R | CA12 2886/4885CA1 1342/4885CA2 633/4885 |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | CA12 1754/4885CA1 908/4885CA2 672/4885 |
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | CA12 4605/4885CA1 4673/4885CA2 4135/4885 |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | CA12 4605/4885CA1 4673/4885CA2 4135/4885 |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | CA12 4605/4885CA1 4673/4885CA2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.